- Home
- UCAR vs NEUP Comparison
UCAR vs NEUP Comparison
Compare UCAR & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- NEUP
- Stock Information
- Founded
- UCAR 2013
- NEUP 1996
- Country
- UCAR China
- NEUP United States
- Employees
- UCAR N/A
- NEUP N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- NEUP
- Sector
- UCAR Consumer Discretionary
- NEUP
- Exchange
- UCAR Nasdaq
- NEUP Nasdaq
- Market Cap
- UCAR 13.3M
- NEUP 12.7M
- IPO Year
- UCAR 2023
- NEUP N/A
- Fundamental
- Price
- UCAR $3.86
- NEUP $7.01
- Analyst Decision
- UCAR
- NEUP Strong Buy
- Analyst Count
- UCAR 0
- NEUP 1
- Target Price
- UCAR N/A
- NEUP $21.00
- AVG Volume (30 Days)
- UCAR 52.7K
- NEUP 22.3K
- Earning Date
- UCAR 07-07-2025
- NEUP 08-15-2025
- Dividend Yield
- UCAR N/A
- NEUP N/A
- EPS Growth
- UCAR N/A
- NEUP N/A
- EPS
- UCAR N/A
- NEUP 0.00
- Revenue
- UCAR $6,067,871.00
- NEUP $15,662,715.00
- Revenue This Year
- UCAR N/A
- NEUP N/A
- Revenue Next Year
- UCAR N/A
- NEUP N/A
- P/E Ratio
- UCAR N/A
- NEUP $4,149.50
- Revenue Growth
- UCAR 124.09
- NEUP N/A
- 52 Week Low
- UCAR $2.30
- NEUP $2.90
- 52 Week High
- UCAR $9.43
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- UCAR 58.97
- NEUP N/A
- Support Level
- UCAR $3.53
- NEUP N/A
- Resistance Level
- UCAR $4.32
- NEUP N/A
- Average True Range (ATR)
- UCAR 0.39
- NEUP 0.00
- MACD
- UCAR 0.04
- NEUP 0.00
- Stochastic Oscillator
- UCAR 58.17
- NEUP 0.00
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.